CISCO-21 - Treat and prevent Long COVID
Research type
Research Study
Full title
Prevention and early treatment of the long-term effects of COVID-19: a randomised clinical trial of resistance exercise.
IRAS ID
294299
Contact name
Colin Berry
Contact email
Sponsor organisation
NHS Greater Glasgow & Clyde
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, most research studies of treatments for COVID-19 have focused on the life-threatening acute illness. There have been very few studies looking at treatments to improve long-term health after COVID-19.\n\nCOVID-19, particularly when this requires a hospital admission, can lead to weight loss and muscle wasting. Muscle strengthening (resistance-based) exercise could improve outcomes in the long term.\n\nWe are looking to do two things:\n\n1) To undertake a research trial of resistance-based exercise for people recovering from COVID-19. The study will involve 220 patients, half assigned at random (50:50 chance) to the exercise group and half assigned to standard care. The main assessment (primary outcome) is the incremental shuttle walk test, measured in metres achieved, at 3 months. Secondary measures include spirometry, grip strength and questionnaires. A blood sample will be obtained for research purposes. We will also request permission for longer term follow-up of health records and record linkage( funding dependent)- a submission to the Public Benefit & Privacy Panel (PBPP) will be made prior to any Record linkage.\n\n2) Develop a process for creating a platform for future trials of new treatments after COVID-19. This will cut the costs of doing future trials, and allow more patients the opportunity to contribute to medical research that will help improve outcomes for people recovering from COVID-19.\n\nOur team is multidisciplinary, multi-ethnic, gender-balanced and drawn from across NHS Scotland, and the University of Glasgow. We are currently leading the Cardiovascular Imaging in SARS-CoV-2 (CISCO-19) study, funded by the Chief Scientist Office, in the West of Scotland, using medical imaging of the hearts, lungs, and kidneys of patients, to understand the impact of COVID-19. We have consulted with members of the public, including people with COVID-19, in designing this study.
REC name
West of Scotland REC 5
REC reference
21/WS/0034
Date of REC Opinion
7 Apr 2021
REC opinion
Further Information Favourable Opinion